Biosimilars Advisory Service : Global Biosimilars Markets – Regulations, Pipelines, and Major Players | G7 | 2015
Latest update: Global Biosimilars Pipeline updated on 31 July 2015
The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 75% of branded biologics sales, the rest-of-world segment includes many markets where treatment rates with branded biologics are currently low due to their high costs. Therefore, opportunity exists for biosimilars to expand the market and provide better access to biologic therapy. Regulators in more than 20 of the growth markets have adopted biosimilars guidelines and are eager to establish their own biosimilars industries. A wide range of companies are embarking on biosimilars development within their domestic markets and overseas. Understanding who the key competitors are in each region is critical to both biosimilar developers and branded biologic companies.
